Chemoradiation using low-dose cisplatin and 5-fluorouracil in locally advanced squamous cell carcinoma of the skin: A report of two cases

Fujisawa, Yasuhiro; Umebayashi, Yoshihiro; Ichikawa, Eiko; Kawachi, Yasuhiro; Otsuka, Fujio

doi:10.1016/j.jaad.2005.12.035

Cited by 42 publications

(27 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Factors increasing the risk for recurrence, metastasis, or death in patients with squamous cell carcinoma of the skin [7,8]the combination of cisplatin and 5-FU [14,15]. Khansur et al [14] reported on seven patients with primary cutaneous SCC and locoregional progression treated with cisplatin and 5-FU.…”

Section: Cytotoxic Chemotherapymentioning

confidence: 99%

Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma

2010

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (SCC) is an already common disorder with a rapidly increasing incidence. Treatment of early disease depends primarily on surgery or destructive techniques. In contrast to the frequency of early SCC, unresectable or metastatic SCC is relatively rare, but potentially life-threatening without clearly proven treatment options. Few rigorous studies of the treatment of advanced SCC have been undertaken. In the past, various agents have been explored in a limited fashion, including chemotherapy (cisplatin, fluoropyrimidines, bleomycin, doxorubicin), 13-cis-retinoic acid, and interferon-␣2a. Clinical activity has been suggested by these trials, but their small sizes, heterogeneous patient populations, and lack of randomization have hindered the use of their results in defining treatment paradigms. Only one rigorous randomized trial has focused on cutaneous SCC. Enrolling 66 patients, that trial randomized patients at high recurrence risk to either observation or postoperative interferon-␣2a and 13-cis-retinoic acid. This treatment did not improve time to recurrence or prevent secondary cutaneous SCC from developing. Though not in the metastatic setting, this study casts doubt on the ability of this regimen to control metastatic disease. Recently, agents targeting the human epidermal growth factor receptor (erlotinib, gefitinib, cetuximab) have displayed preliminary evidence of activity in phase II clinical trials and case series reports. Expression of this receptor is frequent in cutaneous SCC and appears to be prognostically adverse. Only the conduct of rigorous trials, with well-defined endpoints, adequate patient numbers, and preferably randomization, can prove the clinical efficacy of this promising treatment approach and define better therapy for this vexing clinical problem. The Oncologist 2010;15:1320 -1328

show abstract

Section: Cytotoxic Chemotherapymentioning

confidence: 99%

Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma

2010

View full text Add to dashboard Cite

show abstract

“…Sadek et al (1990) reported on 14 patients (13 evaluable) from a prospective observational study for patients with advanced CSCC treated with cisplatin, 5-FU, and bleomycin for 1-4 months. Two case series reported patients achieving a CR with the combination of cisplatin and 5-FU (Khansur et al, 1991;Fujisawa et al, 2006). Khansur et al (1991) reported on seven patients with primary CSCC and locoregional progression treated with cisplatin and 5-FU.…”

Section: Introductionmentioning

confidence: 99%

“…Two of the three patients with a CR were disease free at a 13-month and 24-month follow up. Fujisawa et al (2006) reported on two patients achieving a CR after one or two cycles of cisplatin and 5-FU. In one of the patients, therapy was discontinued after achieving a surgically confirmed CR.…”

mentioning

confidence: 99%

Evidence Based Analysis of Cisplatin for Treating Patients with Cutaneous Squamous Cell Carcinoma

Shao

Xu²,

Zhang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: This analysis was conducted to evaluate the efficacy and safety of cisplatin based chemotherapy for treating patients with cutaneous squamous cell carcinoma. Methods: Clinical studies evaluating the efficacy and safety of cisplatin based regimens on response and safety for patients with cutaneous squamous cell carcinoma were identified using a predefined search strategy. Pooled response rates (RR) of treatment were calculated. Results: In cisplatin based regimens, 4 clinical studies which including 50 patients with advanced cutaneous squamous cell carcinoma were considered eligible for inclusion. Regimens included cisplatin, doxorubicin, or vindesine. Pooled analysis suggested that, in all patients, the pooled RR was 60% (30/50) in cisplatin based regimens. Nausea and vomiting were the main side effects. No grade III or IV renal or liver toxicity were observed. No treatment related death occurred with the cisplatin based treatments. Conclusion: Evidence based analysis suggests that cisplatin based regimens are associated with a good response rate and acceptable toxicity for treating patients with cutaneous squamous cell carcinoma.

show abstract

“…[654][655][656][657][658] These were generally small case series with only a small number of patients with eligible SCCs, or case reports, and are summarised in Table 57. In all of the studies definitive initial treatment with surgery or radiotherapy was not possible.…”

Section: Combination Systemic Treatmentsmentioning

confidence: 99%

“…656 No recurrences or metastasis were reported in the remaining studies, although these were all single case reports. 654,657,658 All of the studies reported adverse events related to chemotherapy. Two treatment related deaths were reported: one of 15 patients had multiorgan failure after hyperthermic isolated limb perfusion 655 and one of 14 died from a pulmonary infection superimposed on lung fibrosis following neoadjuvant chemotherapy.…”

Section: Combination Systemic Treatmentsmentioning

confidence: 99%

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

Chemoradiation using low-dose cisplatin and 5-fluorouracil in locally advanced squamous cell carcinoma of the skin: A report of two cases

Cited by 42 publications

References 20 publications

Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma

Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma

Evidence Based Analysis of Cisplatin for Treating Patients with Cutaneous Squamous Cell Carcinoma

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Contact Info

Product

Resources

About